Billiontoone (NASDAQ:BLLN) Sees Large Volume Increase After Earnings Beat

Billiontoone, Inc. (NASDAQ:BLLN) saw unusually-strong trading volume on Thursday following a stronger than expected earnings report. Approximately 713,533 shares changed hands during mid-day trading, an increase of 179% from the previous session’s volume of 255,680 shares.The stock last traded at $72.51 and had previously closed at $80.83.

The company reported $0.11 earnings per share for the quarter, topping analysts’ consensus estimates of $0.04 by $0.07. The company had revenue of $96.05 million during the quarter, compared to the consensus estimate of $85.85 million. The firm’s revenue was up 113.0% compared to the same quarter last year.

More Billiontoone News

Here are the key news stories impacting Billiontoone this week:

• Positive Sentiment: Q4 results beat and company raised 2026 revenue guidance — BillionToOne reported $0.11 EPS (vs. $0.04 consensus) and $96.05M revenue (vs. $85.85M est.), with revenue up 113% year/year; management raised FY‑2026 revenue guidance to $430M–$445M (well above street consensus). This is the core bullish fundamental catalyst. GlobeNewswire: Earnings & Guidance
• Positive Sentiment: Guggenheim reaffirmed a “buy” rating with a $120 price target — a supportive analyst vote that implies meaningful upside from current levels. Benzinga: Guggenheim Rating
• Neutral Sentiment: BTIG cut its price target from $160 to $140 but kept a “buy” rating — still constructive long-term, though the lower PT trims upside expectations. StreetInsider: BTIG PT Lowered
• Neutral Sentiment: Reported short interest entries show zero/NaN values and a 0.0 days ratio — the data appears unreliable and is unlikely to explain today’s move. (No meaningful short-interest signal.)
• Negative Sentiment: Wells Fargo lowered its price target from $110 to $90 and set an “equal weight” rating — a clear downdraft to near‑term sentiment and one of the more immediate bearish analyst actions. Benzinga: Wells Fargo PT Cut

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Stifel Nicolaus began coverage on Billiontoone in a research note on Monday, December 1st. They issued a “buy” rating and a $145.00 target price for the company. JPMorgan Chase & Co. lowered their price objective on Billiontoone from $150.00 to $145.00 and set an “overweight” rating for the company in a research report on Wednesday, December 10th. Piper Sandler restated an “overweight” rating on shares of Billiontoone in a research report on Wednesday, December 10th. Wells Fargo & Company reduced their target price on shares of Billiontoone from $110.00 to $90.00 and set an “equal weight” rating on the stock in a research note on Thursday. Finally, Zacks Research raised shares of Billiontoone to a “hold” rating in a research note on Tuesday, December 2nd. Six research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $129.57.

Hedge Funds Weigh In On Billiontoone

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Green Alpha Advisors LLC bought a new stake in shares of Billiontoone in the 4th quarter valued at about $436,000. FNY Investment Advisers LLC acquired a new position in Billiontoone during the fourth quarter valued at approximately $497,000. Massachusetts Financial Services Co. MA bought a new stake in Billiontoone in the fourth quarter valued at approximately $13,373,000. Baillie Gifford & Co. bought a new stake in Billiontoone in the fourth quarter valued at approximately $103,786,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Billiontoone in the fourth quarter worth $1,348,000.

Billiontoone Price Performance

The stock has a market capitalization of $3.30 billion and a P/E ratio of 721.70. The company has a 50-day simple moving average of $85.87.

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.